Free Trial
→ $30 stock to buy before Starlink goes public (WATCH NOW!) (From Paradigm Press) (Ad)tc pixel
NASDAQ:PRFX

PainReform 10/1/2025 Earnings Report

PainReform logo
$4.54 +3.17 (+231.09%)
As of 01:49 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

PainReform EPS Results

Actual EPS
-$2.73
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

PainReform Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

PainReform Announcement Details

Quarter
Date
10/1/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

PainReform Earnings Headlines

PRF Technologies Advances DeepSolar Predict™ Toward Commercial Launch as AI Platform Targets Revenue Optimization Across Renewable Energy Markets
May 28 at 8:30 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/28/3302841/0/en/prf-technologies-advances-deepsolar-predict-toward-commercial-launch-as-ai-platform-targets-revenue-optimization-across-renewable-energy-markets.html
PRF Technologies Announces PRF-110 Demonstrated Sustained 72-Hour Analgesic Activity Comparable to Approved, Commercially Available Benchmark in Head-to-Head Preclinical Study
May 26 at 8:30 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/26/3301087/0/en/prf-technologies-announces-prf-110-demonstrated-sustained-72-hour-analgesic-activity-comparable-to-approved-commercially-available-benchmark-in-head-to-head-preclinical-study.html
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.tc pixel
May 29 at 1:00 AM  |  Profits Run (Ad)
Head-To-Head Comparison: Journey Medical (NASDAQ:DERM) & PainReform (NASDAQ:PRFX)
May 24, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30796414
PRF Technologies Announces FDA Clearance of IND Application for OcuRing™-K Phase II Clinical Trial
April 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/28/3282536/0/en/prf-technologies-announces-fda-clearance-of-ind-application-for-ocuring-k-phase-ii-clinical-trial.html
PRF Technologies Provides Year-End 2025 Business Update Highlighting Strategic Progress Across Healthcare and AI-Driven Solar Platforms
March 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/27/3263728/0/en/prf-technologies-provides-year-end-2025-business-update-highlighting-strategic-progress-across-healthcare-and-ai-driven-solar-platforms.html
See More PainReform Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PainReform? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PainReform and other key companies, straight to your email.

About PainReform

PainReform (NASDAQ:PRFX), a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.

View PainReform Profile
Earnings Tools